<DOC>
	<DOCNO>NCT02431806</DOCNO>
	<brief_summary>The purpose study evaluate efficacy , safety , tolerability levomilnacipran ER relative placebo adolescent outpatient ( 12-17 year ) Major Depressive Disorder ( MDD ) . In addition , study design obtain pharmacokinetics ( PK ) data guide dose selection future pediatric study levomilnacipran .</brief_summary>
	<brief_title>Safety Efficacy Levomilnacipran ER Adolescent Patients With Major Depressive Disorder</brief_title>
	<detailed_description>Study LVM-MD-11 randomize , double-blind , placebo- active-controlled , parallel group , fixed-dose study adolescent patient , age 12-17 year . The study approximately 10 week duration : - 1-week screening/washout period - 8-week double-blind treatment period - 1-week double-blind down-taper period Patients meet eligibility criterion Visit 2 ( Baseline ) randomize 1 4 treatment group : placebo , levomilnacipran 40 mg/day , levomilnacipran 80 mg/day , fluoxetine 20 mg/day .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Fluoxetine</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Key 1 . Male female outpatient ; 1217 year age 2 . Meet Diagnostic Statistical Manual Mental Disorders , Fourth Edition , Text Revision ( DSMIVTR ) criteria Major Depressive Disorder ( MDD ) , confirm Kiddie Schedule Affective Disorders Schizophrenia SchoolAge ChildrenPresent Lifetime ( KSADSPL ) 3 . Score ≥ 40 Children 's Depression Rating ScaleRevised ( CDRSR ) Visits 1 2 4 . Clinical Global ImpressionsSeverity ( CGIS ) score ≥ 4 Visits 1 2 5 . Reliable caregiver 6 . Physical examination , vital sign , clinical laboratory test , ECG normal clinically significant Key Psychiatric 1 . DSMIVTRbased diagnosis axis I disorder MDD primary focus treatment 2 . Mental retardation amnestic cognitive disorder 3 ) Significant suicide risk : Suicide attempt within past year OR Investigator judgment ( base psychiatric interview CSSRS ) Key TreatmentRelated 1 . Allergy , intolerance , hypersensitivity levomilnacipran , milnacipran , fluoxetine , selective serotonin reuptake inhibitor ( SSRI ) serotoninnorepinephrine reuptake inhibitor ( SNRI ) 2 . Use prohibit concomitant medication discontinue Other Key Medical 1 . Any current medical condition might interfere conduct study , confound interpretation study result , affect patient safety 2 . Liver enzyme test ( aspartate aminotransferase ) AST and/or alanine aminotransferase ( ALT ) &gt; 2X upper limit normal ( ULN ) 3 . Clinically significant cardiovascular disorder 4 . Seizure disorder risk seizure 5 . Drug alcohol abuse dependence ( within past year ) 6 . Positive urine drug screen blood alcohol</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>